BACKGROUND: The expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) is correlated with tumor invasion and metastases. METHODS: The plasma TIMP-1 concentration was examined preoperatively in 149 patients with gastric cancer who underwent a surgical resection. The cutoff value of TIMP-1 was set at 112.5 ng/ml based on a previous report. These patients were followed up for more than 5 years prospectively. RESULTS: Plasma TIMP-1 was positive in 30 of the 149 patients (20.1%). The overall survival rate was 78.2% at 5 years in patients with negative plasma TIMP-1, while this rate was 26.7% at 5 years in patients with positive plasma TIMP-1. By univariate analyses, T, N, M, and R category, and TIMP-1, were significant prognosticators. Multivariate analyses demonstrated T, N, and TIMP-1 to be significant prognosticators. The survival curve was clearly separated with respect to TIMP-1. CONCLUSION: These results suggest that plasma TIMP-1 is a strong independent prognosticator for the long-term survival of patients with gastric cancer.
BACKGROUND: The expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) is correlated with tumor invasion and metastases. METHODS: The plasma TIMP-1 concentration was examined preoperatively in 149 patients with gastric cancer who underwent a surgical resection. The cutoff value of TIMP-1 was set at 112.5 ng/ml based on a previous report. These patients were followed up for more than 5 years prospectively. RESULTS: Plasma TIMP-1 was positive in 30 of the 149 patients (20.1%). The overall survival rate was 78.2% at 5 years in patients with negative plasma TIMP-1, while this rate was 26.7% at 5 years in patients with positive plasma TIMP-1. By univariate analyses, T, N, M, and R category, and TIMP-1, were significant prognosticators. Multivariate analyses demonstrated T, N, and TIMP-1 to be significant prognosticators. The survival curve was clearly separated with respect to TIMP-1. CONCLUSION: These results suggest that plasma TIMP-1 is a strong independent prognosticator for the long-term survival of patients with gastric cancer.
Authors: M N Holten-Andersen; R W Stephens; H J Nielsen; G Murphy; I J Christensen; W Stetler-Stevenson; N Brünner Journal: Clin Cancer Res Date: 2000-11 Impact factor: 12.531
Authors: M Holten-Andersen; I J Christensen; M Nilbert; P O Bendahl; H J Nielsen; N Brünner; E Fernebro Journal: Eur J Cancer Date: 2004-01 Impact factor: 9.162
Authors: L Manenti; P Paganoni; I Floriani; F Landoni; V Torri; A Buda; G Taraboletti; R Labianca; D Belotti; R Giavazzi Journal: Eur J Cancer Date: 2003-09 Impact factor: 9.162
Authors: Jonas Hansson; Ramachandran S Vasan; Johan Ärnlöv; Erik Ingelsson; Lars Lind; Anders Larsson; Karl Michaëlsson; Johan Sundström Journal: PLoS One Date: 2011-01-19 Impact factor: 3.240
Authors: Leonardo Lorente; María M Martín; Luis Ramos; Juan J Cáceres; Jordi Solé-Violán; Mónica Argueso; Alejandro Jiménez; Juan M Borreguero-León; Josune Orbe; José A Rodríguez; José A Páramo Journal: BMC Neurol Date: 2015-07-11 Impact factor: 2.474
Authors: Charlotte Aaberg-Jessen; Mia D Sørensen; Ana L S A Matos; José M Moreira; Nils Brünner; Arnon Knudsen; Bjarne W Kristensen Journal: BMC Cancer Date: 2018-03-09 Impact factor: 4.430
Authors: Arunee Dechaphunkul; Monlika Phukaoloun; Kanet Kanjanapradit; Kathryn Graham; Sunita Ghosh; Cheryl Santos; John R Mackey Journal: Int J Breast Cancer Date: 2012-09-04
Authors: Olga Prokopchuk; Barbara Grünwald; Ulrich Nitsche; Carsten Jäger; Oleksii L Prokopchuk; Elaine C Schubert; Helmut Friess; Marc E Martignoni; Achim Krüger Journal: BMC Cancer Date: 2018-02-02 Impact factor: 4.430